Fresenius Medical Care Corporation (NYSE:FMS) has earned an average recommendation of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $44.00.

A number of equities analysts have issued reports on the company. Royal Bank Of Canada restated a “neutral” rating and set a target price on shares of Fresenius Medical Care Corporation in a report on Tuesday, August 8th. Zacks Investment Research cut Fresenius Medical Care Corporation from a “buy” rating to a “sell” rating in a report on Wednesday, October 25th. DZ Bank AG restated a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. Finally, BidaskClub cut Fresenius Medical Care Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st.

Fresenius Medical Care Corporation (FMS) traded up $0.43 on Wednesday, reaching $48.75. 85,448 shares of the company’s stock were exchanged, compared to its average volume of 352,115. The company has a quick ratio of 0.98, a current ratio of 1.22 and a debt-to-equity ratio of 0.55. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22. The stock has a market capitalization of $29,751.69, a PE ratio of 21.67, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45.

Several large investors have recently added to or reduced their stakes in FMS. UBS Asset Management Americas Inc. lifted its holdings in shares of Fresenius Medical Care Corporation by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after purchasing an additional 81 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Fresenius Medical Care Corporation during the 2nd quarter valued at about $179,000. FFT Wealth Management LLC bought a new position in shares of Fresenius Medical Care Corporation during the 2nd quarter valued at about $201,000. HPM Partners LLC bought a new position in shares of Fresenius Medical Care Corporation during the 2nd quarter valued at about $221,000. Finally, YorkBridge Wealth Partners LLC lifted its holdings in shares of Fresenius Medical Care Corporation by 19.4% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock valued at $222,000 after purchasing an additional 749 shares in the last quarter. Institutional investors and hedge funds own 2.62% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/fresenius-medical-care-corporation-fms-receives-44-00-consensus-target-price-from-analysts/1683204.html.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.